SHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES
This article was originally published in The Gray Sheet
Executive Summary
SHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES will be introduced at the beginning of the second quarter, the firm says March 1 in announcing its entry into the new line of business. The recently cleared line of laparoscopic irrigation and electrocautery systems was developed by Miami-based Symbiosis, which Sherwood Medical parent American Home Products purchased last September ("The Gray Sheet" Sept. 28, p. 3). The devices will be marketed by the newly developed Sherwood Intrascopic division. Sherwood Medical said in the press release that the Intrascopic division "will be responsible for the company's entry into the rapidly growing minimally invasive surgery market." Robert Egan is vice president and general manager of the new division. The unit, which will operate out of St. Louis where Sherwood is headquartered, currently has approximately 15 employees, including a sales force that exclusively will market Sherwood Intrascopic products. The firm notes that the division is not yet completely staffed. Sherwood Medical says that the development of the new division occurred independently of AHP's acquisition of Symbiosis, which also currently manufactures minimally invasive surgical instruments for Johnson & Johnson's Ethicon Endo-Surgery Division and for Boston Scientific. Sherwood Medical says that Symbiosis will continue to operate as an independent AHP subsidiary, marketing its products through Sherwood Intrascopic as well as other entities. Symbiosis is expected to be one of several sources for Intrascopic division products. Sherwood Medical notes that it continues to pursue "cost effective technologies, both internally and externally, in order to continue developing innovative products" for the Intrascopic division.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.